Government Affairs
Overview
Crowell’s Government Affairs Group has decades of experience helping clients:
- Create and execute success government affairs strategies to achieve business goals.
- Introduce clients to key U.S. decision makers and educate and advocate on behalf of our client’s business and industry.
- Draft, negotiate, and advocate for new legislation and oppose problematic bills for clients.
- Advocate for clients and track and advise on major government decisions and programs in health care, energy, financial services, infrastructure, technology, and other sectors.
- Represent clients in Congressional investigations and help respond to related crises and related issues.
- Provide in-house training to government affairs and business teams.
Contact
Insights
Client Alert | 7 min read | 10.01.26
SEC and FDA Formalize Information-Sharing Framework for Public Companies
On August 31, 2026, the U.S. Securities and Exchange Commission (SEC) and the U.S. Food and Drug Administration (FDA) signed a Memorandum of Understanding (MOU) establishing a formal framework for the two agencies to share non-public information concerning FDA-regulated products and the companies and individuals engaged in their manufacture, distribution, and sale. The MOU was signed by SEC Chairman Paul S. Atkins and Acting FDA Commissioner Kyle Diamantas. It takes immediate effect and runs for three years, subject to renewal, modification, or termination. In a press release, Chairman Atkins described FDA-related disclosures by public companies as having “a significant impact on our markets” and identified the FDA as “a valuable partner in our efforts to administer and enforce applicable disclosure requirements under the federal securities laws.” Acting Commissioner Diamantas framed the MOU as protecting “both the patients who rely on FDA-regulated products, and the public trust that drives health care innovation.”
Firm News | 4 min read | 07.22.26
Firm News | 2 min read | 07.15.26
Publication | 02.11.26
Representative Matters
- Assisted Fortune 15 health care company in addressing government affairs issues related to COVID-19, pharmaceutical drugs and medical device supply and logistics.
- Participated in the creation of a multibillion-dollar fund for U.S. victims of terrorism.
- Recovered $500 million for a private equity fund based in Dubai.
- Worked with industry stakeholders to win repeal of a medical device sales tax that was part of the Affordable Care Act.
- Increased funding to provide free vaccines for dependents of US military personnel.
Contact
Insights
Client Alert | 7 min read | 10.01.26
SEC and FDA Formalize Information-Sharing Framework for Public Companies
On August 31, 2026, the U.S. Securities and Exchange Commission (SEC) and the U.S. Food and Drug Administration (FDA) signed a Memorandum of Understanding (MOU) establishing a formal framework for the two agencies to share non-public information concerning FDA-regulated products and the companies and individuals engaged in their manufacture, distribution, and sale. The MOU was signed by SEC Chairman Paul S. Atkins and Acting FDA Commissioner Kyle Diamantas. It takes immediate effect and runs for three years, subject to renewal, modification, or termination. In a press release, Chairman Atkins described FDA-related disclosures by public companies as having “a significant impact on our markets” and identified the FDA as “a valuable partner in our efforts to administer and enforce applicable disclosure requirements under the federal securities laws.” Acting Commissioner Diamantas framed the MOU as protecting “both the patients who rely on FDA-regulated products, and the public trust that drives health care innovation.”
Firm News | 4 min read | 07.22.26
Firm News | 2 min read | 07.15.26
Publication | 02.11.26
Insights
When Borders Become Bottlenecks: How Pharma Should Adapt to the New Geopolitical Lens
|12.08.25
Pharmaceutical Executive
Auer Deference After Kisor: Alive or “Zombified”?
|04.01.20
ABA Spring 2020: Infrastructure, Vol. 34 No. 4
Government Affairs – Congressional Influence on Rulemaking is on the Rise
|02.27.19
Crowell & Moring's Regulatory Forecast 2019
State of Play: Trump's Regulatory Tapestry – Broad Brushstrokes, Wide-Open Spaces, and Major Opportunities
|05.09.17
Crowell & Moring's Regulatory Forecast 2017
Financial Services — Cybersecurity and New Technologies Take Center Stage
|01.19.16
Crowell & Moring's Regulatory Forecast 2016
Regulatory 2016 - The State of Play
|01.19.16
Crowell & Moring's Regulatory Forecast 2016
Regulatory Forecast 2016: What Corporate Counsel Need to Know for the Coming Year
|01.19.16
a Crowell & Moring LLP publication
F.D.A. to Use A.I. in Drug Approvals to ‘Radically Increase Efficiency’
|06.10.25
The New York Times (subscription required)
Crowell & Moring Adds Republican Co-Chair To Government Affairs Group
|05.01.23
The National Law Journal
Senator Grassley’s Ex-Chief Of Staff Joins Crowell & Moring
|05.01.23
Competition Policy International
- |
05.10.16
Crowell & Moring's Government Contracts Legal Forum
'Fair Pay and Safe Workplaces' Rules Head to White House for Final Review
|05.06.16
Crowell & Moring's Government Contracts Legal Forum
Supreme Court to Consider Congressionally-Conferred Privacy Breach Standing
|04.29.15
Crowell & Moring's Data Law Insights
Cyber Executive Order Continues the Push for Public-Private Partnerships
|02.23.15
Crowell & Moring's Data Law Insights
Professionals
Insights
Client Alert | 7 min read | 10.01.26
SEC and FDA Formalize Information-Sharing Framework for Public Companies
On August 31, 2026, the U.S. Securities and Exchange Commission (SEC) and the U.S. Food and Drug Administration (FDA) signed a Memorandum of Understanding (MOU) establishing a formal framework for the two agencies to share non-public information concerning FDA-regulated products and the companies and individuals engaged in their manufacture, distribution, and sale. The MOU was signed by SEC Chairman Paul S. Atkins and Acting FDA Commissioner Kyle Diamantas. It takes immediate effect and runs for three years, subject to renewal, modification, or termination. In a press release, Chairman Atkins described FDA-related disclosures by public companies as having “a significant impact on our markets” and identified the FDA as “a valuable partner in our efforts to administer and enforce applicable disclosure requirements under the federal securities laws.” Acting Commissioner Diamantas framed the MOU as protecting “both the patients who rely on FDA-regulated products, and the public trust that drives health care innovation.”
Firm News | 4 min read | 07.22.26
Firm News | 2 min read | 07.15.26
Publication | 02.11.26
Contact
Insights
Client Alert | 7 min read | 10.01.26
SEC and FDA Formalize Information-Sharing Framework for Public Companies
On August 31, 2026, the U.S. Securities and Exchange Commission (SEC) and the U.S. Food and Drug Administration (FDA) signed a Memorandum of Understanding (MOU) establishing a formal framework for the two agencies to share non-public information concerning FDA-regulated products and the companies and individuals engaged in their manufacture, distribution, and sale. The MOU was signed by SEC Chairman Paul S. Atkins and Acting FDA Commissioner Kyle Diamantas. It takes immediate effect and runs for three years, subject to renewal, modification, or termination. In a press release, Chairman Atkins described FDA-related disclosures by public companies as having “a significant impact on our markets” and identified the FDA as “a valuable partner in our efforts to administer and enforce applicable disclosure requirements under the federal securities laws.” Acting Commissioner Diamantas framed the MOU as protecting “both the patients who rely on FDA-regulated products, and the public trust that drives health care innovation.”
Firm News | 4 min read | 07.22.26
Firm News | 2 min read | 07.15.26
Publication | 02.11.26










